Heart monitoring and rehabilitation after immunotherapy heart side effects
Part of Heart & circulation, Immune system & allergy clinical trials.
This study looks at how to monitor and help patients who have had heart problems as a side effect of cancer immunotherapy. If you have recovered from such a heart issue, this program may support your heart health and overall recovery during and after cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with cancer (confirmed by a biopsy or other lab test).
- You have had a heart problem caused by your cancer immunotherapy (called ICI-associated cardiotoxicity).
- A team of doctors has checked you and said you have recovered from the heart problem and are ready for rehabilitation.
- You do not have severe heart failure, other acute heart problems, or severe organ failure (like serious liver or kidney disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special rehabilitation program, including traditional Chinese medicine, for people who have had heart muscle inflammation caused by cancer immunotherapy (called immune checkpoint inhibitors). It aims to help you recover and feel better after this side effect.
This study watches heart health in people starting immunotherapy (a cancer treatment that boosts the immune system) by checking blood samples for heart-related markers. It aims to find early signs of heart problems so they can be managed sooner.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study looks at reports from large health databases to find out if certain cancer drugs (checkpoint inhibitors) cause heart problems. It aims to understand which patients have a higher risk, which may help doctors watch for heart issues in the future.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
This research tracks outcomes for cancer patients who developed heart inflammation (myocarditis) while receiving immune checkpoint inhibitor therapy. By studying survival patterns, researchers hope to better understand how to manage this serious side effect and improve care for future patients.
Hear when a new Immune Checkpoint Inhibitor-Related Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.